Novavax's Total Assets for the quarter that ended in Dec. 2023 was $1,797.5 Mil.
Warning Sign:
If a company builds assets at 71.4% a year, faster than its revenue growth rate of 63.5% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Novavax's average Total Assets Growth Rate was 33.30% per year.
During the past 3 years, the average Total Assets Growth Rate was 12.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 71.40% per year.
During the past 10 years, the average Total Assets Growth Rate was 31.10% per year.
During the past 13 years, Novavax's highest 3-Year average Total Assets Growth Rate was 156.20%. The lowest was -16.00%. And the median was 10.70%.
Total Assets is connected with ROA %. Novavax's annualizedROA % for the quarter that ended in Dec. 2023 was -41.31%. Total Assets is also linked to Revenue through Asset Turnover. Novavax's Asset Turnover for the quarter that ended in Dec. 2023 was 0.15.
Novavax Total Assets Historical Data
The historical data trend for Novavax's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Novavax's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Novavax's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Novavax Total Assets Related Terms
Thank you for viewing the detailed overview of Novavax's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NVAX has been successfully added to your 